Compare Medpace Holdings Inc (MEDP) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Trip.com Group Ltd — how do they compare? Medpace Holdings Inc trades at $533.1 (market cap $15.08B), while Trip.com Group Ltd trades at $43.73 (market cap $28.12B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TCOM | |
|---|---|---|
Market Cap | $15.08B | $28.12B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $78.96 |
52-Week Low | $308.88 | $39.84 |
Enterprise Value | $14.55B | $20.82B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
TCOM trades at $44.15, up 4.0% over 24 hours but facing near-term pressure after recent earnings misses and regulatory scrutiny. The stock shows strong fundamentals with a P/E of 6.38 and net income margin of 48.65%, supported by robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Technical indicators signal a bearish trend with resistance at $44-$45, while analyst consensus remains bullish with a $56.72 price target despite recent guidance concerns.
The outlook balances high profitability and undervaluation against regulatory risks and slowing growth guidance. Investment appeal lies in its dominant market position and cash flow strength, but investors face headwinds from antitrust investigations and margin pressure. The stock's current discount to analyst targets presents opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
